Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case‐based approach

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|36|1|258-261

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.36, Iss.1, 2018-02, pp. : 258-261

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Therapeutic Monoclonal Antibodies and Multiple Sclerosis: The Essentials

By  

Medicinal Chemistry, Vol. 14, Iss. 2, 2018-02 ,pp. : 144-154

Bentham Science Publishers

Access to resources Recommend Favorite

Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 8, Iss. 1, 2008-03 ,pp. : 62-68

Bentham Science Publishers

Access to resources Recommend Favorite

Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma

By  

Current Cancer Drug Targets, Vol. 12, Iss. 7, 2012-09 ,pp. : 814-822

Bentham Science Publishers

Access to resources Recommend Favorite

Pomalidomide therapy for myeloma

By Schey Stephen   Ramasamy Karthik  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 5, 2011-05 ,pp. : 691-700

Informa Healthcare

Access to resources Recommend Favorite

Population Pharmacokinetics of Therapeutic Monoclonal Antibodies

By Dirks Nathanael L.   Meibohm Bernd  

Clinical Pharmacokinetics, Vol. 49, Iss. 10, 2010-10 ,pp. : 633-659

Adis International

Access to resources Recommend Favorite